Provided by Tiger Trade Technology Pte. Ltd.

Anebulo Pharmaceuticals Inc

0.8868
-0.1032-10.42%
Volume:48.51K
Turnover:47.98K
Market Cap:36.17M
PE:-4.56
High:1.00
Open:1.00
Low:0.8868
Close:0.9900
52wk High:3.42
52wk Low:0.2999
Shares:40.78M
Float Shares:3.40M
Volume Ratio:3.13
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1945
EPS(LYR):-0.2509
ROE:-69.69%
ROA:-45.04%
PB:4.56
PE(LYR):-3.53

Loading ...

Anebulo Pharmaceuticals posts Q1 net loss

Reuters
·
Nov 14, 2025

Anebulo Pharmaceuticals Board Approves Reverse Stock Split

Reuters
·
Nov 14, 2025

Anebulo Pharmaceuticals reports first quarter net loss of $0.05 per share

Reuters
·
Nov 14, 2025

Anebulo Pharmaceuticals reports Q1 EPS (5c), one estimate (12c)

TIPRANKS
·
Nov 14, 2025

Anebulo Pharmaceuticals, Inc. Q1 EPS USD -0.05

THOMSON REUTERS
·
Nov 14, 2025

Press Release: Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

Dow Jones
·
Nov 14, 2025

Anebulo Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
Nov 08, 2025

Anebulo Pharmaceuticals’ Bold Move: Potential Risks of Going Private with Reverse Stock Split

TIPRANKS
·
Oct 02, 2025

Anebulo Pharmaceuticals Advances Cannabis Toxicity Treatment

TIPRANKS
·
Oct 01, 2025

BRIEF-Anebulo Pharmaceuticals Reports Fourth Quarter And Fiscal Year 2025 Financial Results

Reuters
·
Sep 30, 2025

Anebulo Pharmaceuticals Fiscal Q4 Loss Unchanged

MT Newswires Live
·
Sep 30, 2025

Anebulo Pharmaceuticals Q4 EPS $(0.05) Beats $(0.08) Estimate

Benzinga
·
Sep 30, 2025

Anebulo Pharmaceuticals, Inc. Q4 EPS USD -0.05

THOMSON REUTERS
·
Sep 30, 2025

Press Release: Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

Dow Jones
·
Sep 30, 2025

Anebulo Pharmaceuticals Initiates Phase 1 Clinical Trial of IV Selonabant for Acute Cannabis-Induced Toxicity in Children

Reuters
·
Sep 25, 2025

Anebulo Pharmaceuticals doses first subjects in selonabant study

TIPRANKS
·
Sep 25, 2025

Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, Under Development for Acute Cannabis-Induced Toxicity

THOMSON REUTERS
·
Sep 25, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Cocrystal Pharma, Prenetics Global

Reuters
·
Sep 12, 2025

BUZZ-Anebulo rises as it weighs going-private deal after getting fresh options

Reuters
·
Sep 12, 2025

Anebulo Pharmaceuticals Explores Strategic Alternatives Update

TIPRANKS
·
Sep 12, 2025